Background: The aim of this study was to evaluate an integrated fluorine‐18 fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (PET/MRI) model combining conventional and radiomic features for the noninvasive identification of symptomatic extracranial carotid atherosclerotic plaques. Methods: A total of 200 patients with advanced carotid plaques (78 symptomatic, 122 asymptomatic) underwent hybrid fluorine‐18 fluorodeoxyglucose PET/MRI. Six MRI morphological features (intraplaque hemorrhage, lipid‐rich necrotic core, ruptured fibrous cap, calcification, surface ulceration, and plaque enhancement) and 3 PET metabolic parameters—metabolic uptake, maximum standardized uptake value, and target‐to‐background ratio—were evaluated. A total of 1991 radiomics were extracted from each of the MRI and PET images, respectively. For each modality, 3 types of models were developed: conventional, radiomics, and combined (incorporating conventional and radiomic features). Diagnostic performance was evaluated using multivariate logistic regression and a linear support vector classifier. Results: In MRI‐based analysis, surface ulceration and plaque enhancement emerged as independent predictors of symptomatic plaques. In PET‐based analysis, standardized uptake value and metabolic uptake were identified as significant independent predictors. The PET conventional model outperformed the MRI conventional model in discriminative ability (areas under the curve: training, 0.899 versus 0.755; internal test, 0.926 versus 0.822; temporal validation, 0.878 versus 0.702). The integrated PET/MRI combined model achieved the best performance, with areas under the curve of 0.962 (training), 0.967 (internal test), and 0.926 (temporal validation), significantly outperforming PET‐ and MRI‐based combined models (all P <0.05). Conclusions: The fluorine‐18 fluorodeoxyglucose PET/MRI combined model integrating morphological, metabolic, and radiomic features outperformed other models, supporting its potential as a noninvasive, high‐precision tool for cerebrovascular risk stratification.